DURHAM, N.C., Sept. 27, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced today that the Company has been invited to present at two upcoming biotech industry conferences, including BioContactQuebec 2012 on October 4, 2012 at the Chateau Laurier, Québec, and the 3rd Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference on Thursday, October 4, 2012, at the New York Academy of Medicine, New York, NY.
Jeff Abbey, President and CEO of Argos, will be presenting at the BioContactQuebec 2012, a biopharmaceutical partnership symposium gathering over 300 global participants, and will also be available to participate in one-on-one meetings at the Conference.
Argos' Chief Operating Officer, Frederick M. Miesowicz, Ph.D., will also be presenting at the 3rd Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference. The Conference allows for researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy. In addition, Dr. Miesowicz will also participate on the panel, "Autologous Therapies: Past, Present and Future," to discuss different approaches to bringing autologous products to the market.
About the Arcelis™ Technology
Arcelis is a fully personalized, active immunotherapy technology that captures all antigens, including mutated and variant antigens that are specific to each patient´s disease. It has been shown to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that are associated with toxicity. The technology can be leveraged to manufacture personalized therapies for any cancer or infectious disease.
The Arcelis process integrates readily into many current treatment paradigms, using only a small tumor or blood sample and the patient's own dendritic cells, which are derived and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient sample to program the dendritic cells to target the entire disease-antigen repertoire. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered as an injection into the skin to produce the desired patient-specific immune response.
Arcelis technology also overcomes many of the manufacturing and commercialization challenges that have impeded other cancer immunotherapies. Automated processes allow a single facility to serve all of North America and can be used to treat any cancer or infectious disease with the same manufacturing process and equipment.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate AGS-003 has initiated a Phase 3 study for the treatment of mRCC, and the Company plans to have data from its Phase 2b study of AGS-004 for the treatment of HIV in the second half of 2013. Argos also recently completed a successful Phase 1a study of AGS-009 in patients with lupus.